Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration... Read More
A close look into: AstraZeneca and Merck’s strategic oncology collaboration
AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered... Read More